U.S. Patent for human telomerase catalytic subunit. I printed what I thought was the 1st page of this and 346 pages later the printer stopped. It will take a while to read all this. But this should be good news for Geron.
Geron's low for the week was $1.38 on Dec 23 and Dec 29. The high for the week was $1.50 Dec 30. The avg. volume is slowly going up, the share price should move higher. Three month avg. 1,567,610 shares, ten days avg 1,656,220 shares, the short week avg. volume was 1,925760 shares.
Year end selling for tax lose is over, Geron should start moving up in price.
Good luck in this rigged casino,
Friday, December 30, 2011
Tuesday, December 27, 2011
Geron now a bargain Buy
Geron Now a Bargain Buy by Jeremy Richards on Seeking Alpha. This the last part of article.
The average price target by analysts is now $4 a share.
In the last 6 months, GERN's stock price has dropped from the $4 level down to a recent low of $1.35. In my opinion, the current stock price of $1.41 represents a bargain buy considering GERN has a $150M cash on hand and a current market-cap of $185M and trading just above its book value of $1.34. I believe buying the stock under its 50 day moving average of $1.73 is a bargain. I would be a seller around the 200 day moving average of $2.69.
GERN insiders currently hold 10.3 million shares or 7.8% of outstanding shares. Director Thomas Kiley purchased 64,275 shares on November 22nd, 2011. This is in addition to the 50,000 shares that he purchased at $2.03 on Oct 5, 2011, increasing his holdings to 314,059 shares. The total 114,275 share purchase by Mr. Kiley is significant given that it is the only insider purchase in at least the last eight years. The share purchase is also a sign of confidence in the company.
The Market liked the story, Geron was up 3 whole cent, on over 2.5 milion shares, three month avg is 1,543,416 shares. I'm still waiting for some real good news to take the price to $2.00. Then will sell some and sell some covered called.
Good luck in this rigged casino,
The average price target by analysts is now $4 a share.
In the last 6 months, GERN's stock price has dropped from the $4 level down to a recent low of $1.35. In my opinion, the current stock price of $1.41 represents a bargain buy considering GERN has a $150M cash on hand and a current market-cap of $185M and trading just above its book value of $1.34. I believe buying the stock under its 50 day moving average of $1.73 is a bargain. I would be a seller around the 200 day moving average of $2.69.
GERN insiders currently hold 10.3 million shares or 7.8% of outstanding shares. Director Thomas Kiley purchased 64,275 shares on November 22nd, 2011. This is in addition to the 50,000 shares that he purchased at $2.03 on Oct 5, 2011, increasing his holdings to 314,059 shares. The total 114,275 share purchase by Mr. Kiley is significant given that it is the only insider purchase in at least the last eight years. The share purchase is also a sign of confidence in the company.
The Market liked the story, Geron was up 3 whole cent, on over 2.5 milion shares, three month avg is 1,543,416 shares. I'm still waiting for some real good news to take the price to $2.00. Then will sell some and sell some covered called.
Good luck in this rigged casino,
Monday, December 26, 2011
Geron road to profitability
The long term investor will need a strong stomach, no scardy cats. The biotech investors will not like waiting till Dec 2012 for good results, if any. I have a bad feeling the share price will go below a dollar in the 1st half of 2012.
Here's a few things that may keep the share price above a dollar.
There is a chance of a buy-out or partership with a company with deep pockets.
The brain treatment for cancer GRN1005, results 1st quarter of 2013
The four Phase II trials that end Dec 2012 and results will be in same month.
Good luck in this rigged casino,
Here's a few things that may keep the share price above a dollar.
There is a chance of a buy-out or partership with a company with deep pockets.
The brain treatment for cancer GRN1005, results 1st quarter of 2013
The four Phase II trials that end Dec 2012 and results will be in same month.
Good luck in this rigged casino,
Friday, December 23, 2011
Geron passes out Christmas Bonuses $600,000 split four ways
That's right, four Geron execs split $600,00 in cash bonuses. Geron in November said it would cut 66 jobs and halt its stem cells R&D program to concentrate on its portfolio of experimental cancer treatments. It's a little upsetting, bonuses for the top execs, while cutting jobs and halting its stem cell program. It's not like David Greenwood who makes $618,000 a year needs a $235,800 bonus or Dr. Stephen Kelsey who makes $595,000 a year and his bonus was $156,600. Melissa Kelly Behrs bonus was $107,500 and Jane Lebkowski received $107,200. I think stock options, based performce, are the right type of bonuses. No product or money coming in, no bonuses simple.
I sold 900 shares at $1.42, made a little money. The high for the week was $1.51 on Monday Dec. 19th and the low was $1.35 on Wednesday Dec. 21st. The avg. five day volume was 1,601,720 shares the three month avg was 1,543,410. Maybe we are at the bottom. If the volume and price start to slowly move up we should hit $2.00 by the end of Feb 2012.
Geron this month started two Phase II trials one evaluating its drug GRN1005 in lung ccancer that has spread to the brain. The other using the same drug to treat breast cancer that has spread to the brain. Results some time early in 2013.
Good luck in this rigged casino,
I sold 900 shares at $1.42, made a little money. The high for the week was $1.51 on Monday Dec. 19th and the low was $1.35 on Wednesday Dec. 21st. The avg. five day volume was 1,601,720 shares the three month avg was 1,543,410. Maybe we are at the bottom. If the volume and price start to slowly move up we should hit $2.00 by the end of Feb 2012.
Geron this month started two Phase II trials one evaluating its drug GRN1005 in lung ccancer that has spread to the brain. The other using the same drug to treat breast cancer that has spread to the brain. Results some time early in 2013.
Good luck in this rigged casino,
Thursday, December 22, 2011
Phase 2 for GRN1005 started
MENLO PARK, Calif., December 22, 2011 - Geron Corporation (Nasdaq: GERN - News) today announced the initiation of GRABM-L (GRN1005 Against Brain Metastases - Lung cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from non-small cell lung cancer (NSCLC). GRN1005 is the company`s lead LRP-directed peptide-drug conjugate (LRP-directed PDC) and consists of the cytotoxic drug paclitaxel linked to a peptide (Angiopep-2) that targets the LRP receptor to cross the blood-brain barrier (BBB) and to target tumors in the brain.
"With the treatment of the first patient in the GRABM-L study, we have initiated both of the planned Phase 2 clinical trials of GRN1005 in patients with cancer metastases in the brain, a significant unmet medical need for which there are currently no approved drug therapies," said Stephen M. Kelsey, M.D., Geron`s Executive Vice President, Head of R&D and Chief Medical Officer. "We have been encouraged by the preliminary evidence of anti-tumor activity against brain metastases observed in the Phase 1 study of GRN1005, and we hope to confirm these results in our Phase 2 trials."
Phase 2 Clinical Trial Design (GRABM-L)
The purpose of the Phase 2 study is to assess the efficacy, safety and tolerability of GRN1005 in patients with brain metastases from NSCLC. The trial plans to enroll 50 patients.
GRN1005 will be administered at a dose of 650 mg/m2 by intravenous (IV) infusion every three weeks. The primary efficacy endpoint for the trial is overall (intra-cranial and extra-cranial disease) objective response rate. Key secondary endpoints include duration of overall objective response, duration of overall progression-free survival and six month overall survival.
Rationale for the Study
Cancer in the brain, particularly metastases, currently represents a significant unmet medical need, because drugs that might be effective against these tumor types are not able to efficiently cross the blood-brain barrier and enter the tumor. Preclinical and Phase 1 data indicate that GRN1005 not only transports paclitaxel into tumors inside the brain through LRP1-mediated transport, but also has activity against tumors outside the brain.
Data on safety and tolerability, and preliminary evidence of anti-tumor activity of GRN1005 were documented in two separate Phase 1 multi-center, open-label, dose escalation clinical trials, conducted by Angiochem, Inc., in patients with heavily pre-treated progressing, advance-stage solid tumors and brain metastases (n=56; including NSCLC) and in patients with recurrent or progressive malignant glioma (n=63). Final data were presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in November.
In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m2 of GRN1005 administered as single-agent therapy once every three weeks. The anti-tumor activity was observed against metastases inside the brain as well as in organs outside of the brain, such as the liver, lung and lymph nodes. Among the patients who responded to treatment with GRN1005, were patients who had previously progressed on taxane therapy.
Geron`s clinical development plan for GRN1005 includes two Phase 2 clinical trials in patients with brain metastases arising from either breast cancer (GRABM-B) or non-small cell lung cancer (GRABM-L). Top-line data from both studies are expected to be available by the end of the second quarter of 2013.
About Brain Metastases
Metastases in the brain arising from primary tumors in other organs are associated with considerable morbidity and mortality. Lung cancer is the most common cause of metastases to the brain, followed by breast cancer.
There are currently no approved drug therapies for the treatment of brain metastases. Brain metastases are very difficult to treat because most drugs, including oncology drugs, such as paclitaxel, that are effective against lung cancer, cannot reach the brain at levels that are clinically therapeutic. Drugs are unable to reach the brain because of the blood-brain-barrier (BBB). Transport across the BBB and into tumors is critical for developing effective treatments for cancers in the brain.
About GRN1005
GRN1005 (previously known as ANG1005) is an LRP-directed peptide-drug conjugate (LRP-directed PDC) being developed for the treatment of cancers in the brain. GRN1005 is designed to deliver cytotoxic drug across the BBB and into tumors by exploiting a native mechanism by which essential substances, such as lipids and hormones, are actively transported into the brain through receptors. GRN1005 is comprised of three molecules of paclitaxel linked to a proprietary 19 amino acid peptide (Angiopep-2) that is designed to target the lipoprotein receptor-related protein 1 (LRP1), one of the most highly expressed receptors on the surface of the BBB. Binding to LRP1 facilitates receptor-mediated transport, or transcytosis, across the BBB into the brain tissue. LRP1 is also up-regulated in many tumors, therefore once in the brain, GRN1005 may gain entry into tumor cells using the same receptor by a process known as endocytosis. GRN1005 is a prodrug, which becomes activated in cells after it is cleaved by esterases to release active paclitaxel from the peptide.
This is good news, the market didn't care. Geron up only 2 cent and volume was 1,404,723 shares, nothing great. Geron needs 10 patients out of the 50 to show improvement.
Good luck in this rigged casino,
"With the treatment of the first patient in the GRABM-L study, we have initiated both of the planned Phase 2 clinical trials of GRN1005 in patients with cancer metastases in the brain, a significant unmet medical need for which there are currently no approved drug therapies," said Stephen M. Kelsey, M.D., Geron`s Executive Vice President, Head of R&D and Chief Medical Officer. "We have been encouraged by the preliminary evidence of anti-tumor activity against brain metastases observed in the Phase 1 study of GRN1005, and we hope to confirm these results in our Phase 2 trials."
Phase 2 Clinical Trial Design (GRABM-L)
The purpose of the Phase 2 study is to assess the efficacy, safety and tolerability of GRN1005 in patients with brain metastases from NSCLC. The trial plans to enroll 50 patients.
GRN1005 will be administered at a dose of 650 mg/m2 by intravenous (IV) infusion every three weeks. The primary efficacy endpoint for the trial is overall (intra-cranial and extra-cranial disease) objective response rate. Key secondary endpoints include duration of overall objective response, duration of overall progression-free survival and six month overall survival.
Rationale for the Study
Cancer in the brain, particularly metastases, currently represents a significant unmet medical need, because drugs that might be effective against these tumor types are not able to efficiently cross the blood-brain barrier and enter the tumor. Preclinical and Phase 1 data indicate that GRN1005 not only transports paclitaxel into tumors inside the brain through LRP1-mediated transport, but also has activity against tumors outside the brain.
Data on safety and tolerability, and preliminary evidence of anti-tumor activity of GRN1005 were documented in two separate Phase 1 multi-center, open-label, dose escalation clinical trials, conducted by Angiochem, Inc., in patients with heavily pre-treated progressing, advance-stage solid tumors and brain metastases (n=56; including NSCLC) and in patients with recurrent or progressive malignant glioma (n=63). Final data were presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in November.
In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m2 of GRN1005 administered as single-agent therapy once every three weeks. The anti-tumor activity was observed against metastases inside the brain as well as in organs outside of the brain, such as the liver, lung and lymph nodes. Among the patients who responded to treatment with GRN1005, were patients who had previously progressed on taxane therapy.
Geron`s clinical development plan for GRN1005 includes two Phase 2 clinical trials in patients with brain metastases arising from either breast cancer (GRABM-B) or non-small cell lung cancer (GRABM-L). Top-line data from both studies are expected to be available by the end of the second quarter of 2013.
About Brain Metastases
Metastases in the brain arising from primary tumors in other organs are associated with considerable morbidity and mortality. Lung cancer is the most common cause of metastases to the brain, followed by breast cancer.
There are currently no approved drug therapies for the treatment of brain metastases. Brain metastases are very difficult to treat because most drugs, including oncology drugs, such as paclitaxel, that are effective against lung cancer, cannot reach the brain at levels that are clinically therapeutic. Drugs are unable to reach the brain because of the blood-brain-barrier (BBB). Transport across the BBB and into tumors is critical for developing effective treatments for cancers in the brain.
About GRN1005
GRN1005 (previously known as ANG1005) is an LRP-directed peptide-drug conjugate (LRP-directed PDC) being developed for the treatment of cancers in the brain. GRN1005 is designed to deliver cytotoxic drug across the BBB and into tumors by exploiting a native mechanism by which essential substances, such as lipids and hormones, are actively transported into the brain through receptors. GRN1005 is comprised of three molecules of paclitaxel linked to a proprietary 19 amino acid peptide (Angiopep-2) that is designed to target the lipoprotein receptor-related protein 1 (LRP1), one of the most highly expressed receptors on the surface of the BBB. Binding to LRP1 facilitates receptor-mediated transport, or transcytosis, across the BBB into the brain tissue. LRP1 is also up-regulated in many tumors, therefore once in the brain, GRN1005 may gain entry into tumor cells using the same receptor by a process known as endocytosis. GRN1005 is a prodrug, which becomes activated in cells after it is cleaved by esterases to release active paclitaxel from the peptide.
This is good news, the market didn't care. Geron up only 2 cent and volume was 1,404,723 shares, nothing great. Geron needs 10 patients out of the 50 to show improvement.
Good luck in this rigged casino,
Wednesday, December 21, 2011
Added more at 1.35
At $1.35 I added more shares. Just for a quick trade, any move up above 1.45 and it's sell. Chip the new CEO will made a deal soon on the stem cells, I hope.
Good luck in this rigged casino,
Good luck in this rigged casino,
Friday, December 16, 2011
Geron volume 5 million today
Volume was 5,494,100 today the avg ten day volume is 1,101,076 shares. Why the big increase on Friday. I checked the message board and no one knows. Alot of guesses.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Wednesday, December 14, 2011
Geron Patient #5 Katie Sharify
Stem cell trial halted, but 23-year-old recipient still has hope
http://www.mercurynews.com/bay-area-news...
Stem cell clinical trials were still under way last month when Katie Sharify's car careened off Highway 5, ejecting her through the back window and paralyzing her from the waist down.
Stanford and Valley Medical Center doctors considered Sharify an ideal candidate to test whether an injection of embryonic cells was safe and could help her regain any sensation.
But just two days before she was scheduled to receive the treatment, the Menlo Park company leading the trials canceled the program. Sharify's doctors injected her anyway, giving her a chance, no matter how small, that two million stem cells creeping up her damaged spine could make a difference.On Tuesday, as Sharify, 23, sat in her wheelchair at Santa Clara County's Valley Medical Center, she discussed her mixed feelings about being the fifth -- and for now, the last -- patient in the United States to receive the experimental treatment for paralysis victims.
Words come easily to Sharify; she had been a communications major at USC and a 2006 graduate of Amador Valley High School in Pleasanton, where she had been a member of a future business leaders club.
"I want someone somewhere to see me," Sharify said. "Maybe there's a head of a big company who sees this and says, 'we should help this girl.' "
Good luck in this rigged casino,
http://www.mercurynews.com/bay-area-news...
Stem cell clinical trials were still under way last month when Katie Sharify's car careened off Highway 5, ejecting her through the back window and paralyzing her from the waist down.
Stanford and Valley Medical Center doctors considered Sharify an ideal candidate to test whether an injection of embryonic cells was safe and could help her regain any sensation.
But just two days before she was scheduled to receive the treatment, the Menlo Park company leading the trials canceled the program. Sharify's doctors injected her anyway, giving her a chance, no matter how small, that two million stem cells creeping up her damaged spine could make a difference.On Tuesday, as Sharify, 23, sat in her wheelchair at Santa Clara County's Valley Medical Center, she discussed her mixed feelings about being the fifth -- and for now, the last -- patient in the United States to receive the experimental treatment for paralysis victims.
Words come easily to Sharify; she had been a communications major at USC and a 2006 graduate of Amador Valley High School in Pleasanton, where she had been a member of a future business leaders club.
"I want someone somewhere to see me," Sharify said. "Maybe there's a head of a big company who sees this and says, 'we should help this girl.' "
Good luck in this rigged casino,
Monday, December 12, 2011
Geron Initiates Phase 2 of GRN1005 in Brain Metastases From Breast Cancer
Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.
Good luck in this rigged casino,
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.
Good luck in this rigged casino,
Sunday, December 11, 2011
No news for Geron
Geron volume was only 814,240 shares over five days. Ten day avg. volume was 1,042,103 and three months was 1,517,420 shares. The high for the week was $1.77 on Monday the low $1.55 on Thursday.
Need partners.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Need partners.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Tuesday, December 6, 2011
No news is the story for Geron
No news on the patent case against Viacyte. No news on anyone buying Geron's stem cell program. No news on partnering. No increase in volume or share price.
Just wait and see if "Chip" the new CEO can work some magic.
Good luck in this rigged casino,
Just wait and see if "Chip" the new CEO can work some magic.
Good luck in this rigged casino,
Thursday, December 1, 2011
Geron slowly moving up, why
The patent case against Viacyte is coming to a end. We should have an announcement Thursday or early next week. Hoping it's good news for longs. Geron share price is $1.76 up 9 cent. at 1:36PM.
Good luck in this riggeed casino,
Good luck in this riggeed casino,
Wednesday, November 30, 2011
GRN1005 recruiting patients
That's great news, on schedule.
From Geron Website-
Our clinical development plan for GRN1005 includes a Phase 2 clinical trial in patients with brain metastases arising from NSCLC and breast cancer. If the data from the previously completed Phase 1 trial in metastatic brain cancer are confirmed, and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
We have also entered into a research and collaboration agreement with Angiochem to utilize these receptor-targeting peptides to transport telomerase inhibitors into the CNS.
Good luck in this rigged casino,
From Geron Website-
Our clinical development plan for GRN1005 includes a Phase 2 clinical trial in patients with brain metastases arising from NSCLC and breast cancer. If the data from the previously completed Phase 1 trial in metastatic brain cancer are confirmed, and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
We have also entered into a research and collaboration agreement with Angiochem to utilize these receptor-targeting peptides to transport telomerase inhibitors into the CNS.
Good luck in this rigged casino,
Monday, November 28, 2011
Insider buying a good sign
There’s an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 22, Geron Corp.’s Director, Thomas Kiley, invested $100,269.00 into 64,275 shares of GERN, for a cost per share of $1.56. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.
Good luck in this rigged casino,
Good luck in this rigged casino,
Friday, November 25, 2011
Geron needs a partner
The high and low for the week was on the same day Nov. 21st, Monday, $1.80 and $1.41. The $1.41 was a new 52 week low. Volume was over 3 million for Monday but went back down to normal the next few days.
TJ descided to become active, to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.
Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and raise the money quickly.
I'm going to email Geron and see what they say about my idea.
Good luck in this rigged casino,
TJ descided to become active, to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.
Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and raise the money quickly.
I'm going to email Geron and see what they say about my idea.
Good luck in this rigged casino,
Thursday, November 24, 2011
TJ has descided to become active
TJ descided the become active to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.
Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and raise the money quickly
Good luck in this rigged casino,
Check out Tory's Head in the Clouds blog.
Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and raise the money quickly
Good luck in this rigged casino,
Kiley Thomas doubled down
Kiley Thomas Director at Geron bought 64,275 more shares at $1.56 on 11-22-2011, for a total of 300,000+. He believes or more likely he knows the share price will increase soon, because "Chip" the new CEO is wheeling and dealing.
Any price increase will sell a few shares and sell a few covered calls.
Good luck in this rigged casino,
Any price increase will sell a few shares and sell a few covered calls.
Good luck in this rigged casino,
Tuesday, November 22, 2011
Alex Barkas died suddenly Monday he was on Geron board of directors
Alex Barkas, biotech venture capitalist with Prospect Venture Partners died suddenly on Monday at 64. The cause of death hasn't been determined. He served on the board of Geron.
Geron not adding to Mondays gains, volume flat, share price down 12 cents. No good news yet.
Good luck in this rigged casino,
Geron not adding to Mondays gains, volume flat, share price down 12 cents. No good news yet.
Good luck in this rigged casino,
Monday, November 21, 2011
Nice move up with volume Geron
Closed up 12% with volume over 3.5 million shares. Great. Lets see what happens Tuesday. If we get more volume with a move up then I think we will have good news very soon.
Good luck in this rigged casino,
Good luck in this rigged casino,
GERON the future in bio-tech: CIRM President helping Geron sell stem cell busine...
GERON the future in bio-tech: CIRM President helping Geron sell stem cell busine...: The $3 billion California stem cell agency CIRM, its President Alan Trounson say it is in talks with at least three firms in an effert to sa...
CIRM President helping Geron sell stem cell business
The $3 billion California stem cell agency CIRM, its President Alan Trounson say it is in talks with at least three firms in an effert to salvage Geron's orphan stem cell business. This is great news, it needs to be done very soon, 2 or 3 months tops.
Rumor on Yahoo Message Board is 2nd patient has more than a toe wiggle.
Note Geron's share price is up and climbing on a down big day. Volume is up. I brought 500 shares before I new all this at $1.43. It was interesting because my order was for 1000 shares only 500 filled. I think something is in the works by the price rise on a very very bad day and the volume incease.
Good luck in this rigged casino,
Rumor on Yahoo Message Board is 2nd patient has more than a toe wiggle.
Note Geron's share price is up and climbing on a down big day. Volume is up. I brought 500 shares before I new all this at $1.43. It was interesting because my order was for 1000 shares only 500 filled. I think something is in the works by the price rise on a very very bad day and the volume incease.
Good luck in this rigged casino,
Saturday, November 19, 2011
Geron 5th Patient injected
The Stanford University School of Medicine and Santa Clara Valley Medical treated the fifth patient in the Geron Corp. sponsored trial of a human embryonic-stem-cell-derived treatment for spinal cord injury on Nov. 16th.
Humans may need longer than a year to show results. It was shown that primates require more time than rats to recuperate.
Phase I results for GRN1005, Geron found the peptide/paclitaxel conjugate to be generally well tolerated. Since paclitaxel itself is an approved product, this is good news. Geron plans to initate two Phase II clinical trials for GRN1005 soon [December 2011] with data to become available in the first half of 2013. With good results it will most likely be fast tracked.
ACTC is in two Phase 1/2 trials, which injects embryonic stem cells into the eye, one for Stargardt's Macular Dystrophy and Dry Age Related Macular Degeneration. Interesting news, patients want their second eye injected. That's a very strong indication that they are experiencing improvement. The studies are notable because Catholic nuns are among the patients. That is wild.
I'm long Geron and ACTC.
Good luck is this rigged casino,
Humans may need longer than a year to show results. It was shown that primates require more time than rats to recuperate.
Phase I results for GRN1005, Geron found the peptide/paclitaxel conjugate to be generally well tolerated. Since paclitaxel itself is an approved product, this is good news. Geron plans to initate two Phase II clinical trials for GRN1005 soon [December 2011] with data to become available in the first half of 2013. With good results it will most likely be fast tracked.
ACTC is in two Phase 1/2 trials, which injects embryonic stem cells into the eye, one for Stargardt's Macular Dystrophy and Dry Age Related Macular Degeneration. Interesting news, patients want their second eye injected. That's a very strong indication that they are experiencing improvement. The studies are notable because Catholic nuns are among the patients. That is wild.
I'm long Geron and ACTC.
Good luck is this rigged casino,
Friday, November 18, 2011
Ruff Week for Longs
The high for the week was $2.32 on Nov. 14th the new low for the year was $1.50 on Nov. 18th. The five day avg, volume was 3,607,10 shares, ten day avg. was 2,314,856, three month avg. volume was 1,597,230. We will go lower without positive news. Geron decision to continue pursuing the oncology programs will make or break them. By the end of 2012 if the four Phase II trial results are less then outstanding, I will sell most of my shares. Right now any move over $2.00 will sell a few shares and covered calls.
Partners are still needed.
Good luck in this rigged casino,
Partners are still needed.
Good luck in this rigged casino,
Thursday, November 17, 2011
Setback for the whole stem cell research industry
Joseph Pantginis an analyst with Roth Capital Partners said it would have taken five to ten years before Geron's lead stem cell product reached the market.
This was a classic business calculation, you have two blockbuster programs but only enough money for one, so you choose the one that is further along.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Only good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding I will sell most of my shares. For now any move over $2 I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company.
Good luck in this rigged casino,
This was a classic business calculation, you have two blockbuster programs but only enough money for one, so you choose the one that is further along.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Only good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding I will sell most of my shares. For now any move over $2 I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company.
Good luck in this rigged casino,
Wednesday, November 16, 2011
Geron now totally focused on Imetelstat
Imetelstat could be part initial therapy and maintence thrapy in 90% of all cancers. Whether as a single agent or in combination with other drugs, it looks like a telomerase inhibitor can have a role in cancer treatment. The Phase II trial will answer that question at the end of 2012. If so, Imetelstat may be the first and only drug that has the benefit that hits CSCs. It could be the blockbuster of all time in cancer. That's why GERN decided it could not afford to expend its limited resources on ESCs. It's still very dispointing but with limited funds a choice had to be made.
Good luck in this rigged casino,
Good luck in this rigged casino,
Tuesday, November 15, 2011
Chip buys 80,000 shares Geron
That's the rumor on Yahoo's Message Broad. Chip will do what it takes to made this company survive. Over 9 million shares traded down 20%. I bought at $1.85 and $1.80 pre-market, that was a mistake. I think we'll go back to $2+ after the new year starts.
Again, I'm very disappointed by the halting of the stem cell research. It's very sad.
Geron plans to partner all stem cell program. They will be lucky to get pennies on the dollar.
Good luck in this rigged casino,
Again, I'm very disappointed by the halting of the stem cell research. It's very sad.
Geron plans to partner all stem cell program. They will be lucky to get pennies on the dollar.
Good luck in this rigged casino,
Monday, November 14, 2011
Geron halting stem cell research
Geron to focus on its novel cancer programs.
This is bad short term, good long term. Geron saw the writing on the wall, running out of money fast. They now may have time to get a blockbuster product to market before they have to do a 2nd offering at under $2.00.
Geron plans to partner all stem cell programs, meaning the partner will have to foot the total bill.
The GRN1005 is entering two Phase 2 trials this year data from these trials should be out before the end of the 2nd quarter of 2013.
The four Phase 2 clinical oncology studies will have data by the end of 2012. If any are good Geron will find a partner.
Conference call Nov. 15 at 9AM I will be listening.
I am very disappointed by the halting of the stem cell research. I still believe in the science. Geron needs a very very rich partner to fund this.
We will take a big hit tomorrow. I will buy a few shares around $1.75 or lower.
Good luck in this rigged casino,
This is bad short term, good long term. Geron saw the writing on the wall, running out of money fast. They now may have time to get a blockbuster product to market before they have to do a 2nd offering at under $2.00.
Geron plans to partner all stem cell programs, meaning the partner will have to foot the total bill.
The GRN1005 is entering two Phase 2 trials this year data from these trials should be out before the end of the 2nd quarter of 2013.
The four Phase 2 clinical oncology studies will have data by the end of 2012. If any are good Geron will find a partner.
Conference call Nov. 15 at 9AM I will be listening.
I am very disappointed by the halting of the stem cell research. I still believe in the science. Geron needs a very very rich partner to fund this.
We will take a big hit tomorrow. I will buy a few shares around $1.75 or lower.
Good luck in this rigged casino,
Unlocking Amazing Potential of Stem Cell Therapy
NEW YORK, NY, Nov 14, 2011 (MARKETWIRE via COMTEX) -- The case for increased stem cell funding is growing by the day as the potentially lifesaving effects of regenerative medicine continue to be revealed. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Advanced Cell Technology, Inc. (ACTC, Trade ) and Geron Corporation (GERN, Trade ). Ground breaking studies out of Japan earlier this month showed the vast reach of stem cell medicine. A research team at Japan's RIKEN Center for Developmental Biology successfully used stem cells to synthesize a fully functioning organ entirely from scratch. The team somehow managed to take mouse stem cells and transformed them into a working pituitary gland, which is a small organ that lives at the base of your brain and produces hormones that help you grow.
The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.
Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The company recently reported a loss from operations of $6.9 million for the third quarter ended September 30, 2011. This compares with a loss from operations of $5.4 million reported in the third quarter of 2010.
Geron Corporation is developing cell therapies from differentiated human embryonic stem cellswith the first product in a Phase 1 clinical trial for spinal cord injury. For the third quarter of 2011, the company reported a net loss of $19.5 million, or $0.16 per share, compared to $18.3 million, or $0.19 per share, for the comparable 2010 period
Let's see if this will move the share price. I'm long big time GERN and ACTC.
Good luck in this rigged casino,
The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.
Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The company recently reported a loss from operations of $6.9 million for the third quarter ended September 30, 2011. This compares with a loss from operations of $5.4 million reported in the third quarter of 2010.
Geron Corporation is developing cell therapies from differentiated human embryonic stem cellswith the first product in a Phase 1 clinical trial for spinal cord injury. For the third quarter of 2011, the company reported a net loss of $19.5 million, or $0.16 per share, compared to $18.3 million, or $0.19 per share, for the comparable 2010 period
Let's see if this will move the share price. I'm long big time GERN and ACTC.
Good luck in this rigged casino,
Friday, November 11, 2011
Geron week in review
No great news from Geron, but there was alot of good news stories on stem cells. I believe in the science more each day. Can Geron come up with a FDA approved blockbuster before they run out of money. It will be very very close. GRN1005 is there best shot. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data the product candidate may have an opportunity for early marketing approval. I will feel better about Geron's viability if and when they find a partner with deep pockets.
The high for the week was $2.43 on Nov. 8 and the low was $2.21 on Nov. 10. The volume is very low. Five day avg. volume is 922,200 shares, ten day avg. volume 1,069,566 shares and the three month avg 1,446,080 shares.
I didn't get any $3 calls my bid was to low.
Good luck in this rigged casino,
The high for the week was $2.43 on Nov. 8 and the low was $2.21 on Nov. 10. The volume is very low. Five day avg. volume is 922,200 shares, ten day avg. volume 1,069,566 shares and the three month avg 1,446,080 shares.
I didn't get any $3 calls my bid was to low.
Good luck in this rigged casino,
Wednesday, November 9, 2011
Treating Parkinson's with stem cells
Major step in treating Parkinso's with stem cell transformation. Previous difficulties in transforming stem cells into neurons, which are killed off when Parkinson's disease strike. have now beed resolved. Testing on monkeys has shown the cells not only survived and function normally but begin to reverse the process of poor movement problems. Now the prospect of transplanting freshly grown dopamine producing cells into human patients to treat the disease has been significantly raised.
Stem cell therapy may still be some way off. However, this study has shown for the first time that it is possible to transplant nerve cells that work from human stem cells.
Above is part of a story from Digital Journal Nov 7, 2011 by Kev Hedges.
Looks like the market will be down big. Buy a few shares from your wish list. If Geron goes under $2.20 will buy a few $3.00 calls. Not sure what month.
Good luck in this rigged casino,
Stem cell therapy may still be some way off. However, this study has shown for the first time that it is possible to transplant nerve cells that work from human stem cells.
Above is part of a story from Digital Journal Nov 7, 2011 by Kev Hedges.
Looks like the market will be down big. Buy a few shares from your wish list. If Geron goes under $2.20 will buy a few $3.00 calls. Not sure what month.
Good luck in this rigged casino,
Sunday, November 6, 2011
Geron silent for?
Geron also my be silent because of something happening with the FDA and must be close to some conclusion, and are in a very sensitive time about any leaked infor.
GRN1005 Phase 1 final results Nov. 14th. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
Something good is in the works. May buy some $3 calls.
Good luck in this rigged casino,
GRN1005 Phase 1 final results Nov. 14th. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
Something good is in the works. May buy some $3 calls.
Good luck in this rigged casino,
Saturday, November 5, 2011
Geron week in Review
Geron's high for the week was $2.51 on Monday Oct. 31st. The low for the week was $2.21 on Tuesday Nov. 1st. The avg. volume has been going down only 1,189,440 shares for 5 day avg, 3 month is 1,601,150.
Hoping "Chip" the new CEO will work his magic. Thinking of putting a small bet on Chip's ability. May buy a few Jan 12 $3.00 calls. But after losing $600 the last time I bet on good news coming, I'm a little gun shy.
Good luck in this rigged casino,
Hoping "Chip" the new CEO will work his magic. Thinking of putting a small bet on Chip's ability. May buy a few Jan 12 $3.00 calls. But after losing $600 the last time I bet on good news coming, I'm a little gun shy.
Good luck in this rigged casino,
Friday, November 4, 2011
Patent case against Viacyte
After thinking about the conference call today, the strategic review at the end of this year should move the stock price higher. It was interesting that they keep on saying there would be no comments on forward movement. Why say this? Chip must be working on a deal or deals that will reduce the cash burn with big pharma and not want anyone to say anything to mess it up.
Good news I think in the patent case against on Viacyte. In the latest filing in the case the last paragraph. The parties have been negotiating a settlement. This could be big.
Good luck is this rigged casino,
Good news I think in the patent case against on Viacyte. In the latest filing in the case the last paragraph. The parties have been negotiating a settlement. This could be big.
Good luck is this rigged casino,
End of the Year will talk strategist moves
Listened to call today at 9AM. Nothing that will move share price. All Phase II trial are going well. Cash burn rate for this year will be $65 million. They have $185 million in cash. Strategist talk at the end of this year should be move share price, hopefully up.
Good luck in this rigged casino,
Good luck in this rigged casino,
Thursday, November 3, 2011
Geron beat by 2 cents
It's not as good as it sounds. Geron lost 16 cent a share in the 3Q, the estimate was for a 18 cents a share lost. The revenes fell 60% year/year to 0.22 min vs the 0.97 min consensus. I don't understand why this is going down. With the GE and Corning deal I would think revenes would be going up.
I hope "Chip" has some good news Friday at AM.
Good luck in this rigged casino,
I hope "Chip" has some good news Friday at AM.
Good luck in this rigged casino,
Tuesday, November 1, 2011
Geron Q3 Results Nov 4 at 9AM
Quarterly Financial Conference Calls
November 4, 2011, 6:00am PDT / 9:00am EDT
Q3 2011 Financial Results Conference Call, Menlo Park, CAPlease use the following URL to access the webcast: http://www.media-server.com/m/p/2j4c3p37
Look for increase in Revenue Growth it was down 53.80% . Revenue should start climbing with all there deals with GE, Corning ect. Buy on the dips and start the rips up.
Good luck in this rigged casino,
Friday, October 28, 2011
Geron no follow through
No follow through from Thursday's +3 million shares. Friday's close was $2.56 down 2 cent from Thursday's close. Volume was only 1,392,000. The five day avg was 1,476,060, ten days avg was 1,291,355, three month avg 1,664,870. The high was $2.60 on Friday the low was Wed. $2.20. Hoping for some good news from "Chip" the new CEO, Nov 4th Conference Call to discuss third quarter financial results and highlights. We are above the 50 day moving avg of $2.30, the 200 day moving avg is $3.54.
Good luck in this rigged casino,
Good luck in this rigged casino,
No Follow Through Geron
No follow through today, price down, no increase in volume, no good news was leaked out. I still think "Chip" will throw us a bone Nov 4th. I will be listening.
Good luck in this rigged casino,
Good luck in this rigged casino,
Thursday, October 27, 2011
3 Million Shares Traded
Geron traded 3,037,729 shares today closed at $2.58 up 30 cent or 13%. This is very good, volume with price increase. If we get follow through Friday say 3.5 million shares and a 20 cent price gain, then maybe we have good news coming that will drive the share price even higher. Remember this is why "Chip" was hired as CEO, too get the share price up and get some deals made. Again if we hit $3, I will sell a few covered called.
Good luck in this rigged casino,
Good luck in this rigged casino,
Moving up with Market
Geron is moving up big 8.7% to $2.48. But no increase in volume, we've been through this before. If the volume is not over 2 million today I'm not going to get to excited. With "Chip" the new CEO running the the show now, we could get some good news at the Nov. 4th Conference. Increase in volume with a share price rise is the best sign that some thing good is around the corner. Any move to $3, I will sell a few covered calls.
Good luck in this rigged casino.
Good luck in this rigged casino.
Wednesday, October 26, 2011
Geron the next big thing
For over ten years the leadership was all about the science. Now we have drugs that are products of that science. Geron hires "Chip" as CEO. The man who has a proven track record for making investors money. I see Geron becoming the next big thing. Bigger then AAPL, GOOG or any pharma company. It might take 20 more years but Geron could do it. Always remember you can lose all your money in any stock.
Good luck in this rigged casino,
Good luck in this rigged casino,
Tuesday, October 25, 2011
Right now the fifth patient is being evaluated for GRNOPC1
Right now the fifth patient is being evaluated, for GRNOPC1 phase one trial using stem cells to treat patients with spinal cord injuries.
This is not the time to sell at $2.00. This company could be $25.00 overnight if one of the test patients shows movement. Or if big pharma takes a position $8.00 is possible.
I think a sustainable big jump will take place some time in late spring 2012, when some kind of deal is leaked out and confirmed later. I believe "Chip" is busy doing that job right now.
Good luck in this rigged casino,
This is not the time to sell at $2.00. This company could be $25.00 overnight if one of the test patients shows movement. Or if big pharma takes a position $8.00 is possible.
I think a sustainable big jump will take place some time in late spring 2012, when some kind of deal is leaked out and confirmed later. I believe "Chip" is busy doing that job right now.
Good luck in this rigged casino,
Geron announces Conference Call for Third Quarter
Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights. November 4, 2011 at 9AM Eastern Time. Dial 1-800-706-7748 the passcode is 53572623.
More good data from GRNOPC1
Oct 25, 2011 07:31:09 (ET)
MENLO PARK, Calif., Oct 25, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade)
today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from
human embryonic stem cells, for myelin repair in a non-human primate model. The data supports
further investigation of the potential therapeutic use of GRNOPC1 in central nervous system
(CNS) disorders where the central or contributing pathology is destructive removal of myelin
from nerve axons, such as observed in multiple sclerosis (MS), myelitis and spinal cord injury.
GRNOPC1 is currently in a Phase 1 clinical trial in patients with spinal cord injury.The new
data were presented at the 5th Joint Triennial Congress of the European and Americas Committees
for Treatment and Research in Multiple Sclerosis, in Amsterdam, by Prof. Jeffery D. Kocsis,
Ph.D., from Yale University School of Medicine. The work was performed in collaboration
with scientists at Geron.
The studies utilized a non-human primate model where demyelinated lesions, such as seen
in multiple sclerosis, were induced chemically in the spinal cord. GRNOPC1 was injected
into the demyelinated spinal cord lesions one week after chemical induction. The lesion sites
from six monkeys were analyzed using light and electron microscopy at various timepoints
up to one year after injection of GRNOPC1 to look for evidence of cell survival and
remyelination of nerve axons. In the first few weeks after implantation, the injection sites
contained maturing transplanted cells indicative of a premyelinating phenotype with evidence
of variable numbers and degrees of remyelinated axons. By four months post implantation,
GRNOPC1 had induced extensive and thick myelin around the formerly denuded axons.
Human cells were detected at the lesion site, providing evidence for survival of
transplanted GRNOPC1. There was no evidence of abnormal tissue, tumor formation or
other pathologies associated with the injection of GRNOPC1. Neurological exams of the injected
animals were normal. The data showed in the non-human primate that GRNOPC1 can survive
at the lesion site and progressively remyelination of axons. "These new data confirm and
extend previous results showing that GRNOPC1 can promote remyelination in rodents and
non-human primates," said Jane Lebkowski, Ph.D., Geron's Chief Scientific Officer. "These
results provide further support for the potential of GRNOPC1 to provide therapeutic
benefit in a number of central nervous system diseases, such as MS and myelitis."
About GRNOPC1
Oligodendrocytes produce myelin, an insulating layer made up of protein and fatty substances
that forms around nerves in the CNS to enable them to conduct electrical signals. Without
myelin, many of the nerves in the brain and spinal cord cannot function properly. Oligodendrocytes
are lost in CNS disorders such as spinal cord injury and MS.
GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated
remyelinating, nerve growth stimulating and angiogenic properties leading to restoration
of function in rodent models of acute spinal cord injury. Non-clinical studies have shown that
MENLO PARK, Calif., Oct 25, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade)
today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from
human embryonic stem cells, for myelin repair in a non-human primate model. The data supports
further investigation of the potential therapeutic use of GRNOPC1 in central nervous system
(CNS) disorders where the central or contributing pathology is destructive removal of myelin
from nerve axons, such as observed in multiple sclerosis (MS), myelitis and spinal cord injury.
GRNOPC1 is currently in a Phase 1 clinical trial in patients with spinal cord injury.The new
data were presented at the 5th Joint Triennial Congress of the European and Americas Committees
for Treatment and Research in Multiple Sclerosis, in Amsterdam, by Prof. Jeffery D. Kocsis,
Ph.D., from Yale University School of Medicine. The work was performed in collaboration
with scientists at Geron.
The studies utilized a non-human primate model where demyelinated lesions, such as seen
in multiple sclerosis, were induced chemically in the spinal cord. GRNOPC1 was injected
into the demyelinated spinal cord lesions one week after chemical induction. The lesion sites
from six monkeys were analyzed using light and electron microscopy at various timepoints
up to one year after injection of GRNOPC1 to look for evidence of cell survival and
remyelination of nerve axons. In the first few weeks after implantation, the injection sites
contained maturing transplanted cells indicative of a premyelinating phenotype with evidence
of variable numbers and degrees of remyelinated axons. By four months post implantation,
GRNOPC1 had induced extensive and thick myelin around the formerly denuded axons.
Human cells were detected at the lesion site, providing evidence for survival of
transplanted GRNOPC1. There was no evidence of abnormal tissue, tumor formation or
other pathologies associated with the injection of GRNOPC1. Neurological exams of the injected
animals were normal. The data showed in the non-human primate that GRNOPC1 can survive
at the lesion site and progressively remyelination of axons. "These new data confirm and
extend previous results showing that GRNOPC1 can promote remyelination in rodents and
non-human primates," said Jane Lebkowski, Ph.D., Geron's Chief Scientific Officer. "These
results provide further support for the potential of GRNOPC1 to provide therapeutic
benefit in a number of central nervous system diseases, such as MS and myelitis."
About GRNOPC1
Oligodendrocytes produce myelin, an insulating layer made up of protein and fatty substances
that forms around nerves in the CNS to enable them to conduct electrical signals. Without
myelin, many of the nerves in the brain and spinal cord cannot function properly. Oligodendrocytes
are lost in CNS disorders such as spinal cord injury and MS.
GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated
remyelinating, nerve growth stimulating and angiogenic properties leading to restoration
of function in rodent models of acute spinal cord injury. Non-clinical studies have shown that
administration of GRNOPC1 seven days after injury significantly improved locomotor activity
and kinematic scores of rats with spinal
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic
degenerative diseases. The company is advancing anti-cancer therapies through multiple
Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and
with a compound designed to penetrate the blood-brain barrier. The company is developing
cell therapies from differentiated human embryonic stem cells, with the first product in a
Phase 1 clinical trial for spinal cord injury.
For more information, visit www.geron.com .
and kinematic scores of rats with spinal
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic
degenerative diseases. The company is advancing anti-cancer therapies through multiple
Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and
with a compound designed to penetrate the blood-brain barrier. The company is developing
cell therapies from differentiated human embryonic stem cells, with the first product in a
Phase 1 clinical trial for spinal cord injury.
For more information, visit www.geron.com .
Monday, October 24, 2011
Safety data on GRNOPC1
Safety data to data form the trial has shown:
1.No surgical complications during or after the procedures.
2.No adverse events related to the injection procedures or to GRNOPC1.
3.A few mild adverse events related to tacrolimus.
4.No evidence of cavitation in the spinal cord at the injury sites on MRI.
5.No unexpected neurological changes.
6.No evidence of immune responses to GRNOPC1.
GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without complications from either the cells or the surgical procedure itself, and without any negative effects on the spinal cord or neurological function of the patients to date. The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, including after withdrawal of immunosuppressive drug.
The facts all point to success. We know that these stem cells work. The big question is whether they are safe. We have shown that to date. Geron is positioned for huge increases from this and Oncology programs. Then orchestrated takeover bid most likely scenario, as any review of the new CEO will indicate. Those are the facts. Stock moves up. Market as well.
Good luck in this rigged casino,
1.No surgical complications during or after the procedures.
2.No adverse events related to the injection procedures or to GRNOPC1.
3.A few mild adverse events related to tacrolimus.
4.No evidence of cavitation in the spinal cord at the injury sites on MRI.
5.No unexpected neurological changes.
6.No evidence of immune responses to GRNOPC1.
GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without complications from either the cells or the surgical procedure itself, and without any negative effects on the spinal cord or neurological function of the patients to date. The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, including after withdrawal of immunosuppressive drug.
The facts all point to success. We know that these stem cells work. The big question is whether they are safe. We have shown that to date. Geron is positioned for huge increases from this and Oncology programs. Then orchestrated takeover bid most likely scenario, as any review of the new CEO will indicate. Those are the facts. Stock moves up. Market as well.
Good luck in this rigged casino,
Friday, October 21, 2011
No Interest
Five day avg volume only 1,084,860 shares, ten day avg. 1,281,746 and three month avg. 1,651,130 shares. Market has no real interest in Geron at this time. The high for the week was $2.38 on Monday and low was $2.11 on Wednesday. Share price has been range bound from Sept 22-Oct 21, between $1.87 to $2.38. Only under $2, two days and closed over $2 on those days. Will be buying more on any dips close to $2.
Good luck in this rigged casino,
Good luck in this rigged casino,
GERON the future in bio-tech: Manipulation
GERON the future in bio-tech: Manipulation: Yes, manipulation of share price does happen and is happening. If we get a toe wiggle or the results from the four Phase 2 cancer drug appe...
Manipulation
Yes, manipulation of share price does happen and is happening. If we get a toe wiggle or the results from the four Phase 2 cancer drug appears to be successful none of the Market Makers, hedge funds or institutions will be capable of stopping the huge run up. The market is bigger then any Market Maker or hedge fund. When things are in doubt, fear can be planted and exploited. The Market Makers, hedge funds and institutions will take advantage. They cover, they switch sides but they are not stupid enough to try an stop a big move up. If you believe like I do buy a few shares on the dips. Many are shorting and or are selling, when they should be accumulating. Always, Always remember to can lose all your money in any stock.
Good luck in this rigged casino,
Thursday, October 20, 2011
Geron Q and A Dr. Gold
Dr.Gold, "So far 4 patients have been treated, It was never our intent to publicize their identities or their progress. The first patient was treated a year ago. No adverse effects whatsoever, which was the goal, because it allows us to ramp up the dose from a "safety" range to a "beneficial function" range. Going forward, there will be cervical patients, higher doses, and efforts to break up the scar tissue so that whatever works in subacutes also helps chronics."
Then Q and A
Q: Dr Gold, please tell us something about the patients you've treated at Geron.
A: No, I'm not allowed to talk about that. I do need to say that we'd be delighted, of course.
This is good news, Geron is moving forward. With some luck we might get a toe wiggle. If not now, later with the higher doses.
Good luck in this rigged casino,
Then Q and A
Q: Dr Gold, please tell us something about the patients you've treated at Geron.
A: No, I'm not allowed to talk about that. I do need to say that we'd be delighted, of course.
This is good news, Geron is moving forward. With some luck we might get a toe wiggle. If not now, later with the higher doses.
Good luck in this rigged casino,
Data Update on GRNOPC1 spinal cord injury
Oct 20, 2011 07:30:02 (ET)
MENLO PARK, Calif., Oct 20, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade )
today announced two presentations on the company's ongoing Phase 1 clinical trial of its human
embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Safety data
were presented at the Pre-Conference Symposia of the joint 2011 American Congress of
Rehabilitation Medicine and American Society of Neuro-Radiology Annual Meeting in Atlanta,
GA. A second presentation was given at the Working 2 Walk 2011 conference in Rockville,
MD. The presentations were given by Joseph Gold, Ph.D., Geron's Senior Director of
Neurobiology and Stem Cell Therapies and Linda Jones, P.T., M.S., Geron's Senior Clinical
Trials Manager for GRNOPC1. "We are pleased to report that the lowest intended dose of
GRNOPC1 has been administered to four patients with complete thoracic spinal cord injuries,"
said Stephen M. Kelsey, M.D., Geron's Head of Research & Development and Chief Medical
Officer. "To date, GRNOPC1 has been well tolerated with no serious adverse events."
Phase 1 Clinical Trial Data
Data were presented on four patients with neurologically complete American Spinal Injury Association
(ASIA) Impairment Scale grade A thoracic spinal cord injuries, who received GRNOPC1 at a dose of
two million cells delivered by injection into the lesion site using a syringe positioning device designed by
Geron. GRNOPC1 was administered between 7 and 14 days after injury. Low-dose tacrolimus was
given for temporary immune-suppression from the time of injection for 46 days, at which point the dose
was tapered and withdrawn completely at 60 days.
Endpoints of the trial are safety and evaluation of neurological function, using standardized testing at
specified timepoints to monitor sensory and lower extremity motor function. The trial protocol also includes
multiple MRI scans. Initial follow-up of patients is one year. One patient in the trial has completed the
Day 365 follow-up visit. The most recent patient to be enrolled in the clinical trial has completed the Day
30 follow-up. After one year the patients enter a period of long-term follow-up that includes annual in-
person visits for the first five years and subsequent yearly check-ups via telephone for an additional nine
years.
Safety data to date from the trial has shown:
-- No surgical complications during or after the procedures.
-- No adverse events related to the injection procedures or to GRNOPC1.
-- A few mild adverse events related to tacrolimus.
-- No evidence of cavitation in the spinal cord at the injury sites on MRI.
-- No unexpected neurological changes.
-- No evidence of immune responses to GRNOPC1.
GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without
complications from either the cells or the surgical procedure itself, and without any negative effects on
the spinal cord or neurological function of the patients to date. The only side-effects observed were due
to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection
of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic
cell therapy, including after withdrawal of immunosuppressive drug.
About GRNOPC1
GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating
, nerve growth stimulating and angiogenic properties leading to restoration of function in rodent models of
acute spinal cord injury. Preclinical studies have shown that administration of GRNOPC1 significantly
improved locomotor activity and kinematic scores of rodents with spinal cord injuries when injected seven
days after the injury. Histological examination of the injured spinal cords treated with GRNOPC1 showed
improved axon survival and extensive remyelination surrounding the rodent axons. For more information
about GRNOPC1, visit www.geron.com/GRNOPC1Trial/ . For further information about the Phase 1
clinical trial, including location of clinical sites, visit http://clinicaltrials.gov/ct2/show/NCT01217008 .
About Spinal Cord Injury
Spinal cord injury is caused by trauma to the spinal cord that results in a loss of motor control, sensatory
perception, bowel and bladder control, and numerous other voluntary or involuntary body functions. A
traumatic blow to the spine can fracture or dislocate vertebrae that may cause bone fragments or disc
material to injure the nerve fibers and damage the oligodendrocyte cells that insulate the nerve fibers in the
spinal cord. Most human spinal cord injuries are contusions (bruises) rather than lacerations to the cord.
Every year approximately 12,000 people in the U.S. sustain spinal cord injuries. There are currently no
approved therapies for the treatment of spinal cord injury.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative
diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in
different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the
blood-brain barrier. The company is developing cell therapies from differentiated human embryonic stem
cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. For
more information, visit www.geron.com .
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this
press release regarding potential applications of Geron's human embryonic stem cell technologies and
GRNOPC1 constitute forward-looking statements that involve risks and uncertainties, including, without
limitation, risks inherent in the development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and protection of our intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic
reports, filed with the Securities and Exchange Commission, including the quarterly report on Form 10-Q
for the quarter ended June 30, 2011.
SOURCE: Geron Corporation
MENLO PARK, Calif., Oct 20, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade )
today announced two presentations on the company's ongoing Phase 1 clinical trial of its human
embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Safety data
were presented at the Pre-Conference Symposia of the joint 2011 American Congress of
Rehabilitation Medicine and American Society of Neuro-Radiology Annual Meeting in Atlanta,
GA. A second presentation was given at the Working 2 Walk 2011 conference in Rockville,
MD. The presentations were given by Joseph Gold, Ph.D., Geron's Senior Director of
Neurobiology and Stem Cell Therapies and Linda Jones, P.T., M.S., Geron's Senior Clinical
Trials Manager for GRNOPC1. "We are pleased to report that the lowest intended dose of
GRNOPC1 has been administered to four patients with complete thoracic spinal cord injuries,"
said Stephen M. Kelsey, M.D., Geron's Head of Research & Development and Chief Medical
Officer. "To date, GRNOPC1 has been well tolerated with no serious adverse events."
Phase 1 Clinical Trial Data
Data were presented on four patients with neurologically complete American Spinal Injury Association
(ASIA) Impairment Scale grade A thoracic spinal cord injuries, who received GRNOPC1 at a dose of
two million cells delivered by injection into the lesion site using a syringe positioning device designed by
Geron. GRNOPC1 was administered between 7 and 14 days after injury. Low-dose tacrolimus was
given for temporary immune-suppression from the time of injection for 46 days, at which point the dose
was tapered and withdrawn completely at 60 days.
Endpoints of the trial are safety and evaluation of neurological function, using standardized testing at
specified timepoints to monitor sensory and lower extremity motor function. The trial protocol also includes
multiple MRI scans. Initial follow-up of patients is one year. One patient in the trial has completed the
Day 365 follow-up visit. The most recent patient to be enrolled in the clinical trial has completed the Day
30 follow-up. After one year the patients enter a period of long-term follow-up that includes annual in-
person visits for the first five years and subsequent yearly check-ups via telephone for an additional nine
years.
Safety data to date from the trial has shown:
-- No surgical complications during or after the procedures.
-- No adverse events related to the injection procedures or to GRNOPC1.
-- A few mild adverse events related to tacrolimus.
-- No evidence of cavitation in the spinal cord at the injury sites on MRI.
-- No unexpected neurological changes.
-- No evidence of immune responses to GRNOPC1.
GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without
complications from either the cells or the surgical procedure itself, and without any negative effects on
the spinal cord or neurological function of the patients to date. The only side-effects observed were due
to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection
of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic
cell therapy, including after withdrawal of immunosuppressive drug.
About GRNOPC1
GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating
, nerve growth stimulating and angiogenic properties leading to restoration of function in rodent models of
acute spinal cord injury. Preclinical studies have shown that administration of GRNOPC1 significantly
improved locomotor activity and kinematic scores of rodents with spinal cord injuries when injected seven
days after the injury. Histological examination of the injured spinal cords treated with GRNOPC1 showed
improved axon survival and extensive remyelination surrounding the rodent axons. For more information
about GRNOPC1, visit www.geron.com/GRNOPC1Trial/ . For further information about the Phase 1
clinical trial, including location of clinical sites, visit http://clinicaltrials.gov/ct2/show/NCT01217008 .
About Spinal Cord Injury
Spinal cord injury is caused by trauma to the spinal cord that results in a loss of motor control, sensatory
perception, bowel and bladder control, and numerous other voluntary or involuntary body functions. A
traumatic blow to the spine can fracture or dislocate vertebrae that may cause bone fragments or disc
material to injure the nerve fibers and damage the oligodendrocyte cells that insulate the nerve fibers in the
spinal cord. Most human spinal cord injuries are contusions (bruises) rather than lacerations to the cord.
Every year approximately 12,000 people in the U.S. sustain spinal cord injuries. There are currently no
approved therapies for the treatment of spinal cord injury.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative
diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in
different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the
blood-brain barrier. The company is developing cell therapies from differentiated human embryonic stem
cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. For
more information, visit www.geron.com .
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this
press release regarding potential applications of Geron's human embryonic stem cell technologies and
GRNOPC1 constitute forward-looking statements that involve risks and uncertainties, including, without
limitation, risks inherent in the development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and protection of our intellectual property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic
reports, filed with the Securities and Exchange Commission, including the quarterly report on Form 10-Q
for the quarter ended June 30, 2011.
SOURCE: Geron Corporation
Good luck in this rigged casino
Tuesday, October 18, 2011
Viacyte Case Geron share price will rise
I'm not going into detail on Geron suing Viacyte over patent infringement. It looks like Geron may win. The lawyer at Geron buys 50,000 shares in early Oct. Indicates that the case is going in Geron favor.
Remember the new CEO who has a history of selling to big pharma every time he takes over a new company.
The European court ruling today, Geron benefits with other U.S. based stem cell companies.
Geron price rises and or Geron gets bought out, not the whole company but pieces.
Will be buying more shares and selling cover calls on any price spike. Also will sell a few shares on any price spike.
Remember the new CEO who has a history of selling to big pharma every time he takes over a new company.
The European court ruling today, Geron benefits with other U.S. based stem cell companies.
Geron price rises and or Geron gets bought out, not the whole company but pieces.
Will be buying more shares and selling cover calls on any price spike. Also will sell a few shares on any price spike.
Sunday, October 16, 2011
Geron's Goals for 2012
Regulatory acceptance for OPC1 SC1 thoracic dose escalation Q1/2012
Regulatory acceptance for OPC1 SC1 cervical cohort Q1/2012
Declaration of IND Candidacy for GRN510 Q1/2012
PFS data in imetelstat Phase 2 in NSCLC Q2/2012
PFS data in imetelstat Phase 2 in Breast Cancer Q2/2012
ORR data in imetelstat Phase 2 in Multiple Myeloma Q2/2012
Hematologic response rate in imetelstat Phase 2 in ET Q2/2012
ORR data GRN1005 NSCLC brain mets Phase 2 Q4/2012
ORR data GRN1005 Breast Cancer brain mets Phase 2 Q4/2012.
2012 will be a very important year for Geron. With a new CEO who is a deal maker. The four phase 2 trials ending in Dec of 2012 and results will be reported then. I'm hoping for a $5 to $10 share price. I will be buying a few more shares on the dips and will sell a few shares and or sell some covered calls on the rips up.
Good luck in this rigged casino,
Regulatory acceptance for OPC1 SC1 cervical cohort Q1/2012
Declaration of IND Candidacy for GRN510 Q1/2012
PFS data in imetelstat Phase 2 in NSCLC Q2/2012
PFS data in imetelstat Phase 2 in Breast Cancer Q2/2012
ORR data in imetelstat Phase 2 in Multiple Myeloma Q2/2012
Hematologic response rate in imetelstat Phase 2 in ET Q2/2012
ORR data GRN1005 NSCLC brain mets Phase 2 Q4/2012
ORR data GRN1005 Breast Cancer brain mets Phase 2 Q4/2012.
2012 will be a very important year for Geron. With a new CEO who is a deal maker. The four phase 2 trials ending in Dec of 2012 and results will be reported then. I'm hoping for a $5 to $10 share price. I will be buying a few more shares on the dips and will sell a few shares and or sell some covered calls on the rips up.
Good luck in this rigged casino,
Friday, October 14, 2011
Geron initiate randomized Phase 2 in Breast Cancer
Oct 14th Geron initiates randomized Phase 2 clinical trial of imetelstat in breast cancer. Enrollment of the first patient using a telomerase inhibitor drug GRN163L. The results will be known the end of 2012.
The high for the was on Wed. Oct 12th of $2.38, the low of $2.18 was on Mon. Oct 10th. The avg. volume is going down. The one year update on Oct 16th, on there Phase 1 GRNOPC1 looks like no great news. I'm basing this on no increase in volume or price. I hope I'm wrong.
Good luck in this rigged casino,
The high for the was on Wed. Oct 12th of $2.38, the low of $2.18 was on Mon. Oct 10th. The avg. volume is going down. The one year update on Oct 16th, on there Phase 1 GRNOPC1 looks like no great news. I'm basing this on no increase in volume or price. I hope I'm wrong.
Good luck in this rigged casino,
Tuesday, October 11, 2011
Update on Phase 1 GRNOPC1 Spinal Cord injuries
U2FP, Working 2 Walk, Oct 16th at 9:45AM at Hilton Rockville, Washington D.C. Joseph Gold PhD Senior Director at Geron will give a update on Phase 1 Safety Trial of Human Embryonic Stem-Cell GRNOPC1 in subjects with neurologically complete, subacute spinal cord injuries. Geron is up 5% I think people are hoping for good news Sunday. The volume is not there, yet. Will sell some puts if we get to $3 before the Oct 16th update. If there is an increase in volume say 2 million+ shares a day before update I will not sell puts.
Good luck in this rigged casino,
Good luck in this rigged casino,
Monday, October 10, 2011
Geron and ACTC leading the stem cell revolution
This is from Michael J. Ray's blog on Seeking Alpha. I'm long both Geron and ACTC.
One cannot initiate a discussion of stem cell companies without starting with Geron (GERN). Geron is a company that develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. GERN’s pipelines run fairly deep and besides stem cell technologies it has multiple Phase 2 trials dealing with cancer therapies. That being the case, the real catalyst for the company is the Phase 1 clinical trial dealing with treatment of spinal cord injuries with stem cells. If GERN is going to be the catalyst that starts this medical revolution then it will begin in this trial.
paralysis in many patients. In animal models, Geron was able to show improved functional behavior using GRNOPC1 at the injury site seven days after injury. After much review, the FDA then granted approval for a clinical trial and Phase 1 testing of GRNOPC1 in patients with spinal cord injury began in October 2010. Two clinical sites were opened for patient enrollment in 2010, and the remaining 5 were opened in 2011.What GERN has done is to derived Oligodendrocyte progenitor cells (GRNOPC1) from Human Embryonic Stem Cell (hESCs). Oligodendrocytes are naturally occurring cells in the nervous system that have several functions. They produce myelin (insulating layers of cell membrane) that enables the cells to conduct electrical impulses, plus they also produce neurotrophic factors that support the maintenance of nerve cells. When these Oligodendrocytes are lost in spinal cord injuries, the results are a loss of the myelin and neuronal function that in the end will cause
In late July 2011, Geron stated that a second subject was enrolled and received GRNOPC1 in the ongoing Phase 1 clinical trial. The treatment was administered by investigators at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine. The company also went on to state that the preliminary data from the first two patients showed no safety concerns or serious adverse events. That being the case, Geron received clearance from the FDA to expand the eligibility criteria for the trial to allow inclusion of a wider range of patients.
million. The company also stated that the cash reserve plus the income Geron receives will be sufficient to fund the current level of operations through at least December 2012. Geron also states that future capital requirements will be substantial as several trials are moving forward.For the second quarter of 2011, the company reported a net loss of $21.1 million. Net loss for the first six months of 2011 was $45.5 million and the company ended the quarter with $192.2 million in cash and investments. The total operating expenses for the second quarter of 2011 were $21.9 million which broke down to research and development expenses of $16.5 million and general and administrative expenses of $5.3
So will Geron be the one who will strike first with its stem cell therapy? Phase 1 trials have been going on for awhile and so far all we have really heard is that the therapies are safe but we are still unsure as to how effective they are. It is obvious that the trial is very ambitious and if successful will be a game changer, but one must worry if the company will run out of funding before they get to that point. It will be most interesting to watch as events unfold in this company’s future.
commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. In early 2010 the FDA granted orphan drug status to Advanced Cell for an embryonic stem cell derived treatment for a specific form of blindness, Stargardt’s Macular Dystrophy.If Geron is not moving at the pace you want, then you might want to consider fast acting Advanced Cell Technology (ACTC). Advanced Cell is a biotechnology company focused on the development and
Later that same year the company was cleared by U.S. regulators to test a therapy made from embryonic stem cells in patients with macular degeneration. Advanced Cell wasted little time and by July 2011 the company announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD). These patients were treated at the David Geffen School of Medicine at UCLA and at UCLA's Jules Stein Eye Institute. Notice that the trial is Phase1/2 thereby speeding up the trials. Both the Stargardt's trial and the dry AMD trial will enroll 12 patients each, with cohorts of three patients each receiving an ascending dosage of the stem cells as the trials move forward. The initial dosing was relatively small (50,000 cells) and the early indications were that the patients tolerated the surgical procedures well. In late September 2011, the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s two trials authorized ACTC to move forward with enrolling and treating the next set of patients in each of the trials.
what is going on in Europe. At the same time the DSMB made its announcement, Advanced Cell received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin similar Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy. It should also be known that the European Medicines Agency previously granted Orphan Drug designation for the company's RPE cell product for use in treating SMD. At this point it should be noted that macular degeneration in the U.S. is a $30 billion market with relatively no competition. Add a European market to the mix and the numbers go even higher. To add fuel to the fire one has to consider a recent statement from the CEO when he stated,What should be taken away from this is that the pre-clinical animal findings were extremely successful and if this carries forward in humans then the sky is the limit for the company. Also this is the first time that any testing in Asia had been mentioned. And if all that is not enough, one must also consider the Advanced Cell’s Phase II-approved Myoblast autologous adult stem cell therapy for the treatment of chronic heart failure advanced cardiac disease, myocardial infarction, and ischemia; as well as the Hemangioblast (HG) program for the treatment of blood and cardiovascular diseases which is currently in preclinical development.If that was not enough, then on top of the U.S. trials one must consider
As wonderful as all Advanced Cell’s programs sound, there are still lots of risks with the company. The company basically has no revenue and for the second quarter of 2011; net cash used in operations was $3.2 million. Needless to say the expenses will only increase as the company pushes forward on its clinical trials. Advanced Cell ended the 2011 second quarter with cash and cash equivalents of $16.1 million and will burn through that rather quickly. Add to this a couple newly filed lawsuits and a 1.7 billion share count and we find Advanced Cell in a race for funding. Advanced Cell has stated that several top pharmaceutical companies are closely following the trials and if the company can prove it can eliminate macular degeneration, it is almost certain it will get a joint venture or even a buyout. Until such time though, investors will have to wait and see if this company will be the spark that lights the fires of stem cell revolution.
Good luck in this rigged casino,For now, it will have to suffice to say that we are extremely pleased and believe that these trials will validate our earlier pre-clinical findings. In the meantime, we have begun to set our sights on expanding our clinical trials to in Europe, having been recently approved to begin our SMD trial in the United Kingdom, and various countries in Asia.
Sunday, October 9, 2011
Stem cell treatment for Spinal Cord Injury has Man moving toes
Unfortunately it's not Geron's treatment, but at Beijing Puhua International Hospital. The treatment was on Osama, age 33, male from Libya. The treatment was four neural stem cell injections via lumbar puncture, self stem cell activation and proliferation program, physical therapy and TCM. Out of all that I only understood the physical therapy part. Improvement was made with his sensation and his movements of his toes. Before the therapy he had no sensation or desire for his urination and could not control it. After the treatment he has a sensation when he is urinating and can control 50%. This story should be good for Geron. It's the same science. Geron needs to get the FDA to raise the number of stem cell to 10 million at least. Now it's only 2 million stem cell. Geron should see results like Osama had with an increased dose. With any luck Geron should get it raise by 2nd Q of 2012.
Good luck in this rigged casino,
Good luck in this rigged casino,
Friday, October 7, 2011
Geron week in review
The high for the week was $2.24 on Friday Oct. 7. A new 52 week low of $1.87 on Tuesday Oct. 4. The five day avg volume was 1,845,680 shares, ten day avg volume was 1,625,772 shares and the three month avg volume was 1,626,447. The low is in for now. With the new CEO "Chip" we should move higher. He's a deal maker and we need money. The inside buyer of 50,000 shares on Oct 5 at $2.03 a share was a very good sign.
Better days are coming for Geron.
Good luck in this rigged casino,
Better days are coming for Geron.
Good luck in this rigged casino,
Thursday, October 6, 2011
Inside buying Geron
Kiley Thomas Director at Geron bought 50,000 shares on Oct. 5, 2011 at $2.03 a share. This is a very good sign. No one is going to buy $100,000 worth of stock in a company, they don't believe will make it big time. We need more inside buying like this. I now have 9,600+ shares, if Geron does not make it big, I will be working till I'm 70+.
A one year update on TJ would be nice. TJ was the first person injected with GRNOPC1 in Oct of 2010, using stem cells to treat patients with spinal cord injuries.
Good luck in this rigged casino,
A one year update on TJ would be nice. TJ was the first person injected with GRNOPC1 in Oct of 2010, using stem cells to treat patients with spinal cord injuries.
Good luck in this rigged casino,
Tuesday, October 4, 2011
Who are selling Geron under $2
Only the Scaredy-Cats, who have no business investing. Geron has a cash position of about $1.60 per share and a IP portfolio that has a potential value in the 100's of billions of dollars. If only one of the four platforms work out, the Longs will be very rich. The four platforms are GRNOPC1, GRN163L, GRN1005 and the drug toxicity platform. This is real, nothing has changed except for the management. "Chip" the new CEO is a big plus and will be making deals that will bring cash to Geron. Do your own research there is serious value here. The current price barely covers the cash on hand. If you are a True Believer like myself, buy a few more shares. I did at $1.95. We will be rewarded. A blockbuster is just around he corner. Always remember you can lose all your money in any stock.
Good luck in this rigged casino,
Good luck in this rigged casino,
Going down
The whole market is going down. Geron will break under $2. If you believe in Geron buy a few shares. The people are running scared. Buy the whole market like SPY, DIA, IYY, QQQQ, Market way over sold.
The true believers will be buying. Always remember you can lose all your money in any stock.
Good luck in this rigged casino,
The true believers will be buying. Always remember you can lose all your money in any stock.
Good luck in this rigged casino,
Monday, October 3, 2011
New 52 week low
I added more shares at $2.01. I feel Geron is at the bottom, I thought that at $2.09. If the market goes down more so will Geron. Only a good news story will stop it. If you believe in Geron buy a few shares. Things will get better and Geron will go above $3.00. Remember you can lose all your money in any stock. I'm doing a great job losing mind. True believers start buying.
Good luck in this rigged casino,
Good luck in this rigged casino,
Geron bottom in
Geron has so many positives. The science, money in the bank and now a CEO that is a true businessman famous for making deals. Geron will sell some parts, will have partners and will develop some products. The main thing the days of secondaries are over [at under $10]. I added a few more shares today at $2.09. Remember you can lose all your money on any stock.
Good luck in this rigged casino,
Good luck in this rigged casino,
Saturday, October 1, 2011
Share price will rise
2012 will be a very important year for Geron. With a new CEO who is a deal maker. The share price should go higher. The four phase two trials end in Dec of 2012 and results will be reported then. The GRN 1005 will be in phase two soon if that trial goes well it could get fast tracked. GRNOPC1 in phase one trial, using stem cells to treat patients with spinal cord injuries, any good results would send the share price to the moon. I've been buying all the way down from $4 to $2 avg share price is now $3.80. I will sell a few shares on big prices moves.
Good luck in this rigged casino,
Lee
Good luck in this rigged casino,
Lee
Friday, September 30, 2011
Geron week in review
Geron closed at $2.12 on Friday. The high for the week was $2.31 on Sept 30 and the low was $2.09 on Sept 26. The 50 day moving average is $2.49 which I think it will break in a few months. The new CEO John Scarlett brings on extensive track record of drug development and commercialization success. We will not have another secondary offering. Maybe when it hits $10.
Good luck in this rigged casino
Good luck in this rigged casino
Thursday, September 29, 2011
Geron new CEO
John Scarlett is Geron's new CEO. He has 25 years of executive leadership. A Biotechnology Industry Veteran Brings Extensive Track Record of Drug Development and Commercialization Success.
Conference Call/Webcast Scheduled for 9:00 A.M. ET Tomorrow
This is great news there will be no more secondary stock of offerings. Maybe at $20+. Mr. Scarlett would not take the job unless he saw a great opportunity. Again I feel this is a great move by Geron.
Good luck in this rigged casino
Geron Longs will be rewarded
The true believers in the science, know in the not-too-distant future, the science will trump the market and all long-term investors will be handsomely rewarded. Keep the faith, buy the dips and sell the rips up. Trade around your core holdongs. I buy a few shares on the dips and when it goes up 20-30 cents I sell. Always remember you can lose all your money in any stock.
Good luck in this rigged casino
Good luck in this rigged casino
Wednesday, September 28, 2011
Geron the best
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a conpound designed to penetrate the blood-brain barrier. The four Phase 2 trials end in Q4 of 2012 results shouuld be in Dec 2012. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. Four patients are now in the trial. For more infor visit www.geron.com .
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.
Subscribe to:
Posts (Atom)